Trials / Completed
CompletedNCT02082249
An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications
An Open-Label Three-Part Extension Study Assessing Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 30 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is an extension study to evaluate the long-term safety and tolerability of ABT-SLV187 in subjects with advanced Parkinson's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-SLV187 | Dose levels will be individually optimized |
Timeline
- Start date
- 2014-03-10
- Primary completion
- 2019-10-31
- Completion
- 2019-10-31
- First posted
- 2014-03-10
- Last updated
- 2021-05-12
Locations
7 sites across 3 countries: Japan, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT02082249. Inclusion in this directory is not an endorsement.